Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
#1 Q&A for Christopher Moreau, CEO @ Algernon Pharmaceuticals Inc.
The setup: Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
As the above news release headline states, the company filed a Pre-IND Meeting Request for Chronic Cough. The company has done the same thing for all of it's previous Phase 2 "pilot" studies for COVID-19 and Idiopathic Pulmonary Fibrosis and it's associated cough. The company has also filed Pre-IND Meeting Requests for Small Cell Lung Cancer.
Nov 24, 2021
Please give me a minute.
I will post them up for all to see.
The answers are simply a Yes or No to the question(s).
M$
CORRECTION: The stock markets are closed on Monday. Therefore, I was thinking the Q&A webinar was this coming Tuesday not on Martin Luther King, Jr. Day*
https://thecse.com/en/trading/market-operations
In my opinion, that's a very controversial move to plan such a date on the business calendar.
I mean, it's not like Moreau can tell us any Material News like an official uplist or partnership deal or what's actually going on with the secretive Far East molecule the company acquired but thus far have told us jack shit else about it. Who it's from - what's it's purpose - will it come with a development partnership? Or, maybe he can tell us more about the secret molecule but surely not the other stuff. Maybe, he can shed light on IF the company will meet it's stated goal to start the Phase 1 DMT in January 2022 or does COVID-19 creep back into the excuses picture?
One has to wonder why they chose to hold a Q&A on a holiday?
Does MLK Day remain a controversial and insignificant holiday in Canada as it would appear in some states in the USA?
Either way, it's a Federal holiday and all money stops moving on Monday, January 17, 2022.
The words coming out of the CEO's mouth come Monday better not be disappointing and boring BS.
A ZINGER would be IF a Press Release was issued on Monday morning with Material News.
https://www.investopedia.com/terms/m/materialnews.asp
Now ^that would be a smart move before a Q&A on a frigging holiday.
peace 2x
M$
That's way too many shares. That's selling off yet another half than half of the company for a paltry amount of money. Keeping in mind the mindset of management thus far involves TOXIC FINANCING with Shares + Warrants. So 4M outstanding shares would come with an additional 2M Warrants. We may as well be fast approaching 10M outstanding shares when those warrants dump on the cheap. The share price needs to be at 30 $ or above before they go for our jugular again. They don't have unlimited credit. People are so quick to forgive and forget. Think of it this way - 4M outstanding shares means Algernon's stock price would be 25 $ at 100M $ market cap. Now apply 25 $ to your current holdings and ask yourself has all the time wasted chasing a profit been worth it? My answer is HELL NO. What management needs to do is let the Nasdaq market decide the company's market value once uplisted AND Algernon has completed the DMT phase 1 and Ifenprofil phase 1 clinical trials. Those are minimal costs that may provide the most bang for our buck before any capital raises. If Moreau goes right back to diluting us after two reverse splits this shit is a by the numbers scam job set up for insiders to continue to rape rob and pilfer any long term profits. No. 4M shares outstanding is nowhere near where we should be headed before a billion dollar market cap. Those who know math know the outstanding shares needs to remain low to give us any chance at real profits - worthwhile - life changing profits - the likes of which Moreau said out loud was the goal prior to the latest reverse split. It's time the grown ass man lives up to his words. We need to hold him 100% accountable not COVID-19. This shit is not a game. Boy, do I have the #1 and #2 best questions for Moreau come Tuesday - IF I can make the time for the Q&A. I actually do do other stuff daily beyond pulling out my phone to send posts. If I know I can't get in on the live feed I will post up my 2 questions beforehand hoping someone anyone will ask those questions if not thought of already. My guess - is based on having read the posts around the investors water coolers - no one has as of yet.
peace
M$
CEO Presentation, Deep Dive, and Audience Q&A with Christopher Moreau
Learn how Algernon is lowering the development risks and costs of drug development by repurposing existing approved drugs for new applications.
Algernon is a drug repurposing company that investigates safe, already-approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations, and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the United States or Europe to avoid off-label prescription writing.
Attendees will be able to ask management questions on the webinar.
Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional level discussion and Q&A. Market Radius is hosted by Martin Gagel, former top-ranked sell-side technology and special sits analyst. By registering to this webinar you agree to receive a weekly emails from Radius Research, from which you can unsubscribe at any time.
algernonpharmaceuticals.com/
Jan 17, 2022 01:15 PM in Pacific Time (US and Canada)
us02web.zoom.us/webinar/register/3516421079149/WN_HR39jXeUTju4KqY78QF3HA
Pile on? Are you serious? Maybe you should do some historical due diligence and see where it all started and continued to no end. Put it this way, I would have never known about this trash stock had it not been thrown in my face elsewhere as some alternative investment to another stock. As all the other junk stock predictions piled on year after year - none of those panned out either. Keep believing!
Yeah, wait to hear back.
Likely the a winners of cold chicken dinners.
Meanwhile...sub sandwich under 3 $ may be the consolation prize.
M$
Thank you shell. It looks better than before for sure.
M$
yeah...that'll likely do the trick -_-
It looks like your true blue winner is on the brink of sub $3. Given your perceived expertise about uplisting to Nasdaq, please let me know what your new theory will be once your winner drops below $3 per share. How many months now has it been since simplicity applied for an uplist? It's not so simple eh? smh
Oh, Nav varsh ki shubhkamnaayein !!!
M$
It looks like your true blue winner is on the brink of sub $3. Given your perceived expertise about uplisting to Nasdaq, please let me know what your new theory will be once your winner drops below $3 per share.
Oh, Nav varsh ki shubhkamnaayein !!!
M$
The powers that be wont let me back to mod. However, what I'd do is take down everything in the IBOX. It's old old old and outdated. What would be nice is a simple drag and drop of the Corporate Fact Sheet as the IBOX header and information. The only link to add thereafter would be the CSE (has all relevant filings/bulletins/reports/etc). That's all the information needed without cluttering up the IBOX with opinions or other numbers that continue to change like the outstanding shares. The Fact Sheet and CSE link covers all the bases for anyone looking to do their own basic due diligence. Crazy how you can't get any others to step up from year to year but surely some of the 180+ followers have come out of the shadows to chime in on negative news. smh
One Opinion,
M$
Likes/Dislikes Regarding: Corporate Fact Sheet
algernonpharmaceuticals.com/wp-content/uploads/2018/01/Corporate-Fact-Sheet-Jan7-22-Int-f.pdf
Like: Management dropped the timeline to start a stand-alone Phase 2 clinical trial for Chronic Cough
Like: DMT Stroke Phase 1 Begins Q1 2022
Like: DMT Stroke Phase 2 Begins Q4 2022
Like: Pancreatic Cancer Phase 1 Begins Q3 2022
Like: Small Cell Lung Cancer Phase 1 Begins Q3 2022
Like: Algernon plans to be the first company globally to investigate DMT for stroke in humans
Like: Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
Dislike: Algernon management remains beholden to Smackie Mackie Research (Research Capital) and Andre Uddin
Dislike: A huge Smackie Mackie banner of recognition
Dislike: Smackie is a Toxic Financing Pimp
Dislike: Andre Uddin pumped then dumped the COVID-19 data
www.researchcapital.com/people (Research)
algernonpharmaceuticals.com/mackie-research-report/
^Uddin's analysis @ 80 cent CAD was a lowball number given what was on the plate at the time. Yet, that lowball number was still never achieved. It was a lose lose all around. It would have been refreshing to just dump all the losing narratives of years past...like burying the IPF/CC AU/NZ once and for all.
Like: Algernon's program specifically investigates compounds that have never been approved in the U.S. or Europe.
Like: We protect our lead compounds with method of use, dosing and new formulation patents, as well as composition of matter patents that include derivatives and analogues.
Like: ...seeking new regulatory approvals in billion dollar global disease markets
Dislike: Market Cap - C$ 8.40 Million
Like: Active Links Throughout Document
Dislike: No direct mention of NASDAQ application
Like: Algernon plans to be the first company globally to investigate DMT for stroke in humans and is planning to begin a Phase 1 clinical trial in Q1, 2022.
Like: "...we look forward to an exciting year ahead" - Moreau
^ One Opinion
I love the thought of not running any Phase 2 clinical trials before the Phase 1 clinical trials have completed. It would provide shareholders with the best possible shot at increased share price before another capital raise. Hence, keep the outstanding shares ultra low!!! Ultra Low being somewhere in the 2 Million Shares Outstanding range.
M$
They've accepted companies fresh out of bankruptcy. How's that?
M$
Just saying one must assume all stock options previous and present would be exercised by the next report to come up with that bottom line outstanding number. I'm guessing they haven't pulled the trigger on all of them yet if any. They have until the cow jumps over the moon.
One Opinion,
M$
The lung fibrosis pipeline thins
www.evaluate.com/vantage/articles/analysis/spotlight/lung-fibrosis-pipeline-thins
The operative word is "Compensation". Management believes it's earned its keep on this (merry) go-down.
96000 Options represents 4.5% of the overall diluted Common Shares, Warrants, Agent Warrant Units, Stock Options = 2,130,470 Full Diluted Shares.
96,000 stock options exercisable at $4.10 for five years from date of grant = One tenth (1/10th) of the 52 Week High of $41.00 CAD
A 90% Discount.
^That's the insane part of management compensating itself by any rationale it chooses.
I for one do not see how they have earned it by any stretch of the imagination, but hey it's a new year and nothing will surprise me when it comes to management looking out for themselves 1st and foremost.
Lesson Learned the overwhelmingly hard way.
Things that would warrant any options passed around like candy at rock bottom prices is a Nasdaq Listing (while each of us still has vital signs), a Grant(s) to help fund clinical trial(s), a partnership to fund clinical trials, no more toxic financing with family and friends and Cayman Islands and/or any deal that includes toxic warrants and Smackie Mackie and Andre Uddin (Mackie's insider anal-yst).
Nasdaq/Grants/Partnerships/Abolishing Toxic Financing
Addressing any of those issues and management will be doing something it has yet to accomplish.
Thus far, we can only rely on the past practices of management and that's a primary reason the market remains highly skeptical of Christopher Moreau's public plea to shareholders that the best is yet to come.
When, How?
Christopher Moreau has stuck his neck out in a major way with his latest interview with Streetwise Reports.
Christopher Moreau laid the blame of Algernon's abysmal market cap at the feet of his home countrymen.
That's the type of shit you better be able to back up once it rolls out of your mouth with forethought.
Christopher Moreau has publicly pleaded to shareholders' faces on Biopub webcast, in corporate news releases, and the Streetwise Reports interview that Algernon Pharmaceuticals must uplist.
Thus, time is not on our side as Algernon moves forward with it's agenda and in need of financing at some point.
Will they run the same plays as always?
I must say i lack confidence in Christopher Moreau’s Streetwise Reports interview when he stated:
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
by Natan Ponieman
December 30, 2021 9:37 am
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for investors and entrepreneurs alike.
If 2020 was the year psychedelics companies were placed on the map, 2021 was when they began expanding their territory and entering the realms of big finance and mainstream capital.
With scientific evidence for the therapeutic potential of psychedelic substances becoming harder to ignore, this year numerous companies developing psychedelic drugs into viable medical treatments received institutional support from major U.S. exchanges and legacy investment banks.
While overall sector performance became subpar during the latter half of the year, 2021 was definitely a win for the psychedelics sector, which is steadily building on a firm bedrock toward the development of a paradigm-shifting disruption in mental health treatment.
Psychedelics Companies Hit Major U.S. Exchanges
In 2021, the psychedelics industry disembarked on Wall Street, providing it exposure to millions of retail investors around the globe.
The 2020 go-public rush that launched dozens of psychedelics companies into venture exchanges in Canada and the U.S. OTC market became impossible to ignore when several of these companies began uplisting into major U.S. Exchanges like the NASDAQ and the NYSE.
In October, the number of psychedelics companies listed in the U.S. reached 50. Nine of these are currently listed on the NASDAQ and the NYSE, including:
Atai Life Sciences ATAI +0.39%
Compass Pathways CMPS +4.25%
MindMed MNMD +10.1%
Field Trip Health, Inc. FTRP +0.81%
Seelos Therapeutics SEEL +4.91%
Enveric Biosciences ENVB +10.8%
Pasithea Therapeutics Corp. KTTA +1.13%
GH Research GHRS +2.79%
Cybin Corp CYBN +0.42%
The First Psychedelics ETFs Are Born
Growing attention towards the psychedelics space translated into the launch of the first psychedelics-focused exchange-traded funds.
The Horizons Psychedelic Stock Index ETF (NEO: PSYK) became the first ETF to focus solely on the psychedelics industry, debuting in Toronto’s NEO exchange in late January.
Horizons was followed by Defiance ETF, which launched the Defiance Next Gen Altered Experience ETF PSY +3.30% in May, becoming the first psychedelics ETF to go public in the U.S.
Both these ETFs are passive, meaning they each track a specific index that is restructured periodically.
In September, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector: the AdvisorShares Psychedelics ETF PSIL +5.34%
Private Funding Nearly Doubles
While many psychedelics start-ups chose to list on public exchanges as a strategy for raising growth capital, others relied on private placements, which reached record numbers in 2021.
According to a November report by CB Insights, equity funding in the space reached $595 million by the end of October, in 45 different deals. At that run rate, the company projects 55 overall deals this year, possibly surpassing $724 million by the year-end. This figure would double 2020’s added sum of $358 million.
CB Insights notes that almost half of the deals (48%) went into drug research and developing, a vertical with the sector’s highest barrier to entry, but also promises significant returns in the medium term.
This newly found capital availability made way for hundreds of new start-ups that sprouted around psychedelics. It is estimated there are at least 10 times as many private start-ups in the space as there are publicly-listed companies.
Investment Banks Jump Into The Mush Rush
As yet another mark of psychedelics’ graduation into the big leagues of finance, several investment banks and financial services firms launched coverage of companies in the sector.
RBC Capital Markets, Cantor Fitzgerald, Credit Suisse, Citigroup, Aegis Capital, Berenberg, Canaccord Genuity, Cowen & Co, Roth Capital and Maxim Group now provide analysis on the most prominent psychedelics companies, with very promising ratings often in the Buy or Outperform categories.
Regulation, Media Presence And Scientific Progress
The financial tailwinds the psychedelics industry received this year are a reflection of events happening on a much broader scale, supported by an entire growing ecosystem composed of regulatory victories, private and academic research progress and a shift in public acceptance.
On the regulatory front, several new jurisdictions decriminalized psychedelic substances this year including Detroit, Seattle, four Boston suburbs and several cities in Massachusetts and California.
The progress of psychedelics legalization at the state level also reached unprecedented levels with a number of states, including Texas, California, Florida, Colorado, New York, Michigan, Massachusetts, Pennsylvania, Vermont, Iowa, Missouri, Connecticut and Maine, either presenting or passing bills meant to expand therapeutic access to psychedelic substances.
Scientific progress towards a better understanding of psychedelic molecules and their interactions with the human body and mind also grew substantially during 2021. Several universities and research institutions undertook new programs dedicated to the study of psychedelics, including New York University, UC Berkeley Center, UT Austin, Icahn School of Medicine at Mount Sinai and University of Wisconsin–Madison.
Academic research into psychedelics was also encouraged to grow via partnerships between for-profit companies and academic institutions looking to fund their research, like Mydecine Innovations’ (NEO: MYCO) research agreement with Johns Hopkins University and Atai’s Partnership With Harvard's Massachusetts General Hospital.
Lastly, the media played a substantial role in disseminating the therapeutic potential of psychedelic treatments. Psychedelics were featured in cover stories published in the New York Times, the LA Times and the Washington Post and became the central theme in several TV shows and documentaries, including "Nine Perfect Strangers," a miniseries starring Nicole Kidman, which made its debut on Hulu in August.
Picture made from images by Photo by Didssph and Photo by Sean Pollock on Unsplash.
https://www.benzinga.com/markets/cannabis/21/12/24821983/2021-was-the-year-psychedelics-conquered-capitalism-or-is-it-the-other-way-around
Bottom line is Psychedelics are being pushed by big money on all fronts - Public/Private Funding - Investment banks- Regulations/Laws - Media - Scientific community.
Algernon Pharmaceuticals stands alone in it's quest for Stroke treatment There isn't one other Psychedelic company out there of a reported 100 public and private Psychedelic companies that are pursuing Stroke. If management can play its cards right this go around it could become a media darling out of all the Psychedelic companies out there. The key to it all remains the Nasdaq listing. Nasdaq unlocks all the doors mentioned in the above article.
One Opinion,
M$
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
By Lorimer Wilson of munKNEE.com
Sunday, January 2, 2022 2:40 AM EST
The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 6 constituents from our Pure-Play Marijuana Drug Stocks Index sub-category and 12 from our Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which index performed the best in 2021? Which constituents contributed to their performances? How do they compare? This article has the answers.
One hundred (100) clinical-stage psychedelic drug stocks now trade on North American stock exchanges. Sixty (60) of them (see here) research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them) and 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know). The criteria for inclusion in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $35M (only eight have market caps below $100M) and only 18 of those 100 psychedelic drug stocks meet that criteria.
Pure-Play Marijuana Drug Stocks Index
The constituents in both our Pure-Play Marijuana Drug Stocks Index and our Pure-Play Psychedelic Compounds-Based Drug Stocks Index have hyperlinks to 3 areas of additional information which are imperative for any individual considering investing in this sector:
The company name is hyperlinked to its website to provide you with a description of the company and an analysis of its stock.
The trading symbol is hyperlinked to additional financial data and commentary on the company (where available).
The percentage increase YTD is hyperlinked to a chart of the company's stock performance YTD.
The "financial distress" percentage is sourced from macroaxis.com (visit the site and type in the stock symbol to obtain detailed financial data on the health of the company).
The 6 marijuana-based clinical-stage stocks went DOWN -35.7% in 2021. The performance of the constituents in 2021 are presented below in descending order:
Allied Corp. (ALID): UP +136.0%
engaged in the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder
has about a 24% chance of experiencing some form of financial distress in the next two years of operation
Zynerba (ZYNE): DOWN -12.9%
operates as a clinical stage specialty pharmaceutical company
has more than a 55% chance of experiencing financial distress in the next 2 years of operation
Tetra Bio (TBPMF): DOWN -40.0%
engages in the discovery and development of immunomodulator drugs including PPP003 for painful dry eye and uveitis pain and HCC011 for hepatocellular carcinoma
has about a 28% chance of experiencing financial distress in the next 2 years of operation
Revive (RVVTF): DOWN -44.9%
focuses on the research and development of therapeutics for rare disorders and infectious diseases
has a very small chance of experiencing financial distress in the next few years
Corbus (CRBP): DOWN -50.4%
focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer
has a greater than 89% chance of experiencing financial distress in the next few years of operation
Enveric (ENVB): DOWN -78.2%; yes, -78.2%
developing cannabinoid medicines for cancer care such as radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy
has over a 58% chance of experiencing financial distress in the next 2 years of operation
The munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index
The 12 psychedelic compound-based clinical-stage stocks are divided into 2 groups based on their market capitalizations.
The 9 constituents with market caps below $1B were DOWN -32.4% in 2021 and their performances are presented below in descending order:
Seelos (SEEL): UP +3.2%
focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
has over a 74% chance of experiencing financial distress in the next few years of operation.
Awakn (AWKNF): DOWN -6.0% since launch on June 23rd
engaged in researching and developing psychedelic drugs focuses to treat addiction as well as delivering psychedelic treatments for addiction in clinics in the UK and EU.
has a 50% chance of experiencing financial distress in the next 2 years of operation.
Read: Awakn Life Sciences: Wake Up To The Huge Potential
Cybin (CYBN): DOWN -20.0%
focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
has over a 62% chance of experiencing financial distress in the next few years of operation.
Field Trip (FTRP): DOWN -24.3%
focused on building centers for psychedelic therapies across North America and Europe.
has about a 27% chance of experiencing some form of financial distress in the next two years of operation.
Small Pharma (DMTTF): DOWN -30.6% since launch in June, 2021
focused on developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.
has over a 77% chance of experiencing some form of financial distress in the next two years of operation
Mind Medicine (MNMD): DOWN -54.8%
focused on the development of a pipeline of treatments to address addiction and mental illness based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
has over a 58% chance of experiencing financial distress in the next few years of operation.
Numinus (NUMIF): DOWN -50.0%
provides clients with testing of controlled compounds such as LSD, ketamine, DMT, MDMA, mescaline, psilocybin and psilocin as well as conducting research of both MDMA and psilocybin to treat PTSD, depression, anxiety, and addiction.
has over a 77% chance of experiencing financial distress in the next few years of operation
Red Light (TRUFF) DOWN -56.0%
plans to produce, market, and distribute a premium health and wellness brand of psilocybin truffles within the Netherlands.
has less about a 25% chance of experiencing financial distress in the next few years of operation.
Mydecine (MYCOF): DOWN -68.6%; yes, -68.6%!
focused on clinical trials focusing on veterans, EMS, and first responders with a PTSD indication.
has about a 24% chance of experiencing some form of financial distress in the next two years of operation.
The 3 constituents with market caps above $1B were DOWN -16.5% in 2021 and their performances are presented below in descending order:
GH Research (GHRS): UP +21.2%
Compass Pathways (CMPS): DOWN -53.6%
Atai (ATAI): DOWN -57.7%
On average, the 12 constituents in the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index went DOWN -33.6% in 2021 and now have an average market capitalization of $410M.
In Summary
In answer to the opening question as to which Index did the best in 2021:
the munKNEE Pure-Play Marijuana Drug Stocks Index went DOWN -35.7% in 2021
the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index went DOWN -32.4% in 2021
the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index of all 18 constituents went DOWN -33.6% in 2021.
https://talkmarkets.com/content/year-end-summary-marijuana--psychedelic-compounds-based-drug-stocks-index-went-down-336-in-2021?post=339769
Key takeaways:
- One hundred (100) clinical-stage psychedelic drug stocks now trade on North American stock exchanges.
- 35M USD Market Cap is the floor for the above 100 stocks
- GH Research stands head and shoulders above all other companies in terms of Market Cap (1.25B to date) and Gains (21.2%) in 2021.
Also, GH Research is a one-trick pony with DMT @ Phase II.
https://www.ghres.com/pipeline
M$
Don’t let ‘shelved assets’ gather dust. Make them into new lifesaving drugs
By Annette Bakker Dec. 13, 2021
Life-science companies have changed the world with the breakthrough vaccines and therapeutics they created — and continue to create — to combat Covid-19. And thanks to the new technologies they developed during the pandemic, new medicines for other diseases could be just around the corner. But shelved assets — existing compounds gathering dust on companies’ shelves — may represent another round of medical miracles just waiting to be tested in clinical trials.
The development of new treatments inevitably involves ideas that don’t pan out. Though pharmaceutical companies generally patent these ideas, when further research and development into them ceases they become shelved assets that get no more attention.
But “shelved” doesn’t have to mean “permanently abandoned.” In the hands of other researchers with different ideas, they might have the makings of lifesaving therapies.
A handful of biotech companies have already shared their shelved assets. But many large companies hang on to them, even though they have no current intention of developing them further. Their reasons for doing so range from a lack of resources necessary to transfer the asset over to an interested party to a culture that rewards bringing assets in — and not letting them out.
It takes years and billions of dollars to bring a new drug from early lab research through clinical trials to regulatory approval. Many initially promising medications are winnowed out during this process: some turn out to have negative side effects, others don’t work as intended. But drug companies sometimes pull the plug because of unfavorable market dynamics. A recent literature review by Yale researchers found that “strategic business decisions” were the second-most common reason for companies to suspend development of experimental medicines, trailing only “a lack of efficacy” but ranking ahead of “safety problems.” An earlier study found that, between 2013 and 2015, 24% of the drugs that entered clinical trials were stopped for reasons unrelated to safety or efficacy.
In a world of limited resources, it can make good business sense to prioritize one line of research over another in pursuit of the best return on investment. But a trial drug that didn’t work out for one company could still be viable for another. Different focuses, expertise, and balances of risk can all come into play.
Biotech startups will often take chances that big players won’t. Many want a shot at turning shelved assets into big winners as treatments. But to do so, they need access to the patents and other relevant intellectual property.
Large pharmaceutical companies can launch this next wave of innovation by sharing their shelved assets with other companies. This can be a win-win-win situation: If the new team develops a successful therapy, the big fish can share in the profits and thousands of lives are made better or even saved.
Some big firms have begun to understand this potential. Pfizer, with the help of non-profit and private investors, founded SpringWorks Therapeutics, which assesses the potential for shelved assets to develop into new treatments for rare tumors and cancers. This spin-out now has multiple drugs in late-stage trials.
The potential here is global in scope. Japanese behemoth Takeda just licensed one of its previously shelved assets, sapanisertib, to Calithera Biosciences, a small biotech based in San Francisco. Calithera plans to test the drug’s efficacy against lung cancer.
Many researchers are excited about the possibility of combining sapanisertib with brigatinib, one of Takeda’s on-the-market cancer drugs, to treat neurofibromatosis 2, a rare genetic condition that causes tumors to grow along children’s nerves, leading to hearing loss, vision loss, and balance issues. The combined compounds may suppress the proliferation of neurofibromatosis 2 tumor cells.
This effort is personal for me. My organization — the Children’s Tumor Foundation — participates in the Milken Institute’s BRIDGE Initiative, which is aimed at transforming old medicines into new treatments. This approach is particularly important for children with cancer, since many of them, like those with neurofibromatosis 2, don’t have any FDA-approved drugs available to them.
Repurposing shelved drugs that have already been proven safe in humans can save companies millions of dollars and years of research and development, allowing potential treatments to reach kids — and adults — with cancer and other diseases as quickly as possible.
Other companies should join these efforts by licensing shelved assets or spinning out new companies to develop and commercialize them. They have a real opportunity here to capitalize from their unused discoveries — and make a difference in the lives of millions of people along the way.
Annette Bakker is the president of the Children’s Tumor Foundation and a coauthor of the Milken Institute’s report, “Creating a Nonprofit Marketplace for Shelved Drugs: Lessons from a Pilot Project.” The foundation has received funding from Takeda and SpringWorks to support several events.
www.statnews.com/2021/12/13/dont-let-shelved-assets-gather-dust-turn-them-into-lifesaving-drugs/
Cannabix grants options to buy 3.68 million shares
2021-12-30 16:31 ET - News Release
Mr. Rav Mlait reports
CANNABIX TECHNOLOGIES GRANTS STOCK OPTIONS
Cannabix Technologies Inc. has granted 3.68 million incentive stock options to officers, directors and consultants of the company, exercisable at 55 cents per share for five years, of which 1.4 million options will be subject to vesting provisions.
We seek Safe Harbor.
https://www.stockwatch.com/News/Item/Z-C!BLO-3189905/C/BLO
Thank you kind sir. eom M$
Hey Mods - Can we get the correct ticker restored here?
AGNPF
Thank you,
M$
In regards to the Streetwise Reports interview, Christopher J. Moreau hit the nail on the head. CSE/OTC is filled with dumb down investors. Nasdaq is the key to better valuation. Better avenues for capital. Better all around governance of the company. Better outside analysis of the company by globally respected analysts. No more PP's. The list goes on and on. However, it is a fact the CEO has driven the company over a cliff YOY and he must take responsibility for the bonehead decision to bury the Chronic Cough study into the IPF study. That was an immeasurable blow to momentum for the company. IMO we have been set back by years with these studies versus stat sig powered clinical trials. That's the most fundamental error of the Repurposed Drugs strategy. What we have believed until now is entering the clinical trial phase @ Phase 2 meant we leapfrogged past Phase 1 and it's 1 to 2 year time frame which shortens the time to get to Phase 3. The reality is the Repurposed Drugs Strategy thus far has been 1 to 2 years at Phase 2 non powered studies to determine if Algernon will run stat sig powered studies at Phase 2. It effectively turns our Phase 2 timeline into 4 years and more. We thus far have spent 2 years at Phase 2 for Chronic Cough in Australia/New Zealand - timeline is Q2 2020 to Q2 2022 for a "potential" Data readout. The current "standalone Chronic Cough clinical trial is pending for Q2 or Q3 2022. I'm so outdone with all this shit I can't keep track of when shit is supposed to start because it always seems to get pushed back. In any event, the point is not going straight to real world clinical trials versus sidebar studies are what's killing us off. The PP's are not moving the ball down the field. That must stop now! The PP's must stop now! We need the Nasdaq uplist ASAP. I'm very concerned about it not being any timeline or clue coming from the CEO regarding IF/When we will uplist. We are twisting in the wind again my friends. One can only hope the next money play by management doesn't involve selling off another huge chunk of the company to make a minimal splash at getting to some stat sig data. We also hope management can take a page from Bellus Health's playbook and aggressively get a Data Readout inside of 1 year for Chronic Cough. Either the shit works or it doesn't. Don't take another 2 years to find out! Finally, it was very very disheartening to see the CEO not mention Bellus Health and/or the likes of GH Research in his latest display of Pure Comparisons. Moreau defaulted to 2 companies with pipelines that do not resemble Algernon's pipeline. I thought it to be a weak comparison to potential market cap valuations for Chronic Cough and DMT. He should have made room for those comparisons. Leaving them out left me with the belief Moreau is now thinking lowball numbers when it comes to an overall valuation of the company's current pipeline. We’ve truly got ourselves a High Stakes - High Wire act going into Q1 2022. I’m not sure Christopher J. Moreau would rather have it any other way.
DEPICTION Of A MOVE TO NASDAQ
One Opinion,
M$
A PostScript Blast From the Past
investorshub.advfn.com/boards/read_msg.aspx?message_id=134916371&txt2find=515354
Tuesday, 09/26/17 02:34:59 PM
Algernon Looks To US For Help Fighting Strokes
www.streetwisereports.com/article/2021/12/29/co-looks-to-us-for-help-fighting-strokes.html
M$
Agreed. I see no point in using numbers that don't exist as if they are numbers that do exist. That's my point. Simply operate from fact based information. It's not hard to do. We all have followed this company long enough to know enough about the numbers to know BS when we see it. My other point remains an uplist to Nasdaq should eliminate the ongoing basement bargain bin fire sale family and friends plan that has raped robbed and pilfered the rest of us over the years. It cannot be the same BS moving forward. The share structure with 6 YEARS everyone's money wrapped up in such a tiny amount of shares requires management to be smart about dilution moving forward and making the most out of any capital raises. yeah, it's F'd up that Moreau and the rest of them don't really have any skin in the game beyond whatever shares they dole out to themselves to sell along the way. if they personally owned a number of shares in the controlling interest realm we could take what dilution they execute seriously. However, they can continue clowning around as in the past. We hope Christopher can find some moral guidance coupled to Nasdaq guidance that will right the ship and pull us out of the Abyss we find ourselves in every year at this time of year. Can our Loser's Land CEO finally score a win for the little guys?
Who knows?
peace 9x,
M$
PostScript
People on the outside looking in (Newbies) do not know the shit we have endured to get this far. Management knows damn well that each share now represents a 100 shares for us - and each share represents 200 shares for those holding shares from the 1st reverse split orchestrated by Moreau for the bogus studies rolled out to date. We won't forget the past and we won't forgive Christopher Moreau for any BS he pulls moving forward. he's a grown ass man who knows right from wrong. As moronic as he may be naturally - it's not a valid excuse. The stakes are way too high now. Simply do the math! I hope he get's no sleep thinking about how he has royally screwed over shareholders and how to make it right with shareholders by making good on his recent words to all of us:
"The best is yet to come." - Christopher Moreau, CEO @ Algernon Pharmaceuticals Inc.
the 540k number doesn't exist and neither should any PP's.
again, go back to the filings.
the uplist is the key.
Period
peace 8x,
M$ still keeping it real & real simple.
umm I caught it late
I posted it to the wrong message board. sorry about airing out that bankrupt company stuff. surely it's a frustrating thing. been there. done that with a spin off company way back called Torino Ventures. It was one of those Kulwant Malhi (King Cobra) type deals where shareholders got a piece of a spin off company where all shares were locked up until management (Rav Mlait the CEO @ Cannabix) bled the company dry of cash. those shares sat on my book for I think 2 years. pissed me off every time I pulled up my portfolio. couldn't get rid of them. yeah, I know your pain and frustration.
peace 7x,
M$
Question: What is your question?
Kevausha
the prior dilution leading up to consolidation represents 6 fold (6x) dilution of Algernon since the reverse takeover back in 2018. to get to 54 Million share
dilution would be more than 25 fold (25x) dilution from the current outstanding. that's an insane amount of dilution given where the company currently sits with it's pending clinical trials. therefore, such dilution is highly not likely IF the company gets uplisted to Nasdaq. without an uplist, yeah we're all F'd!
also note - that 54.4 million number y'all are riffing about is not a real thing. it does not exist in the real world - in the official filings. one could also riff about the term "unlimited" authorized shares. yeah, theoretically you could issue a gadzillion shares but at some point reality sets in.
M$
Fully Diluted Shares per MDA dated November 26, 2021:
Issued and outstanding common shares 1,674,868
Warrants outstanding 356,670
Agent Warrant Units outstanding 15,432
Stock options outstanding 83,500
Fully Diluted Shares 2,130,470
MDA page 22: sedar-filings.thecse.com/00037722/2111271721209538.pdf
peace 3x,
M$
PostScript for 2.5M Fully Diluted
A maximum of 369,530 shares doled out for a capital raise would be the best case scenario for shareholders not getting killed by dilution (fire sale). 369,530 shares is nearly 25% of the company (outstanding shares). How much will management sell off for it's next capital raise since consolidation? Get the two Phase 1 clinical trials for DMT/Stroke and Ifenprodil/SCLC completed first. Then see where the stock price is at with Nasdaq.
True..there surely remains Family & Friends & Cayman Islands in the picture, but that's not what will govern the oversight of the company once uplisted. In the current CSE (Red Sea/Dead Sea) structure ain't nobody looking under the deck of the company to see what's really going on. Nasdaq is a different animal. They're much more aggressive with oversight requirements (see links in last post). Independent analysts will be poking around along with a slew of other independent entities. You can't go after big money and think your sh!t don't stink if it actually does. They will flush that out immediately. You must clean up your act. Period. Hence, new Chairman Of The Board, new Chief Financial Officer, and word that Kulwant Malhi (Head Of The Snake) slithered off into the desert sands. Time will tell, but surely Nasdaq is an entirely different animal.
peace 2x,
M$
What in particular are you looking to see and please post it if found?
Also, those "Traders Trading Traders" are not real traders.
They are TRAITORS trading on information we do not have at our disposal.
It's the type of crazy ass sh!t they use the Conflicts Of Interest clause to shield themselves from lawsuits.
M$
Nasdaq will eliminate many of the previous types of shenanigans:
listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5600-series
listingcenter.nasdaq.com/rulebook/nasdaq/rules
You won't find any vague - crazy ass - standalone "Conflict Of Interest" clause like the one plastered near the beginning of every Management Discussion & Analysis (MDA) and numbered in the Table of Contents in every Annual Information Form (AIF) and other filed documents.
Word on the street is King Cobra (Kulwant Malhi) slithered off into the sunset along with Michael Sadhra (The Bookkeeper). It appears that Moreau has since began lining up (Chairman of the Board, Chief Financial Officer) the majority of the Board Of Director with his former pals from Miraculins. That's definitely a worry to be had and watched closely. Especially given Miraculins was a colossal failure (reverse split dilution machine) for its shareholders as well. Moreau even had his brother in at Miraculins. Just Crazy Ch!t A!nt !t? As I keep saying, the Nasdaq uplist is the ballgame here. Without it, it's more of the same family and friends fire sale plan. There's no turning back at this point for anyone holding pre-split shares. You remain sitting at rock bottom of the cliff waiting for Moreau's repurposed drugs strategy to revive a dead stock and cold story. The other big key here is dilution moving forward. If Moreau and clan start diluting again like drunken sailors pre-split shareholders are toast. Many already need at least $30 per share to break even from the 2nd reverse split (1 for 100) and you need $60 per share to break even if you're holding shares from the 1st reverse split (1 for 2). Moreau thinks people just forget about all his failures. WE DON'T. Will Moreau ever rack up any measurable successes ("catalysts") at Algernon? It remains a year over year question and concern.
peace,
M$